Loading the session
Loading the session
Loading instrument
$13.38
−0.45%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $13.44 on 4 Nov 2026: 50.2% below the 52-week high of $27.00 (6 Nov 2025) and 11.5% above the low of $12.05 (4 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: −32.3% (SPY −1.6%). 3 months: −33.1% (SPY −0.4%). 1 year: −45.7% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: STVN, SPY · as of 4 Nov 2026
The 4 Nov 2026 close of $13.44 was 33.4% below its 50-day average ($20.17) and 25.5% below its 200-day average ($18.04). It has closed below the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed above the 200-day on 6 Aug 2026, 63 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 4.4M shares was 8.8× the average of the 30 sessions before it (501.7K), as the price fell 4.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
The 14-session relative strength index closed at 19.9 on 4 Nov 2026, its 2nd session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
November 3, 2026
−28.57%March 4, 2026
+18.81%May 9, 2024
−21.59%